[Antiviral action of combined use of rhizoma Polygoni cuspidati and radix Astragali on HSV-1 strain].
The clinical action of combined use of Rhizoma Polygoni Cuspidati and Radix Astragali on HSV-1 was investigated with a view to developing a new antiviral drug. The action was analyzed by way of plaque reduction assay and median-effect principle. In the HEp-2 cell system, if the combination ratio of Rhizoma Polygoni Cuspidati and Radix Astragali was 1(ED50):1(ED50) then, (1) In directly annihilating HSV-1 F strain, when the plaque reduction rate was 20%-80%, and the combination index was < 1.0, there was synergism. (2) In inhibiting the multiplication of HSV-1 F strain, when the plaque reduction rate was 20%-60%, and the combination index was < 1.0, there was also synergism. (3) In blockading HSV-1 F strain infection, when the plaque reduction rate was 20%-90% and the combination index was < 1.0, there was synergism. So this ratio of 1(ED50):1(ED50) should be the first choice for combination. The treatment index of the above two Chinese medicinal herbs equals 10(3), and the cytotoxicity is not potentiated, indicating that the combination is helpful as a virucide for HSV-1 F strain.